State of Cardiovascular Disease and Stroke in Hispanic/Latino Adults in the United States: A Scientific Statement From the American Heart Association
Synopsis
This American Heart Association scientific statement summarizes the current epidemiology of cardiovascular disease and stroke among Hispanic/Latino adults in the United States, noting that cardiovascular disease became the leading cause of death in this population in 2022, that Hispanic adults carry a disproportionate burden of cardiometabolic risk factors including obesity, diabetes, and dyslipidemia, and that substantial differences exist across Hispanic heritage groups, sexes, and disease types, such that the "Hispanic paradox" is increasingly seen as an oversimplification; it further sets priorities including expanding disaggregated data collection, increasing research representation, and ensuring equitable implementation of precision medicine approaches including genomics, multi-omics
Interpretation
The statement reports that cardiovascular disease became the leading cause of death among Hispanic individuals in the United States in 2022, while Hispanic adults experience a disproportionate burden of cardiometabolic risk factors including obesity, diabetes, and dyslipidemia. Relative to prior narratives that treated this population as monolithic and emphasized comparatively lower mortality, the statement places "leading cause of death" alongside "disproportionate risk factor burden," reframing the cardiovascular risk picture for this population. As an American Heart Association scientific statement, its conclusions rest on synthesis of existing epidemiological evidence, expressed in the text through phrases such as "in 2022," "leading cause of death," and "obesity, diabetes, and dyslipidemia"; the text does not provide specific sample sizes or effect sizes.
The statement emphasizes that Hispanic populations are highly heterogeneous, with substantial variation in genetic ancestry and sociocultural influences, and that disaggregated data reveal substantial differences in risk profiles and disease burden among Hispanic heritage groups. Relative to the traditional practice of treating Hispanic populations as a single unit, the statement explicitly makes heritage-group variation a core dimension for understanding risk and outcomes. The basis is the differences shown by disaggregated data as described in the text; this is an inductive statement about existing data, and the text does not list specific group-level values.
The statement holds that the "Hispanic paradox"—lower cardiovascular disease mortality despite higher risk factor burden—is increasingly recognized as an oversimplification that does not apply uniformly across Hispanic heritage groups, sexes, or disease types. Relative to existing understanding that treated the paradox as a stable phenomenon, the statement redefines it as a localized phenomenon that must be examined separately by heritage group, sex, and disease type. This judgment comes from re-examining the scope of the paradox; the text phrases it as "increasingly recognized as an oversimplification," placing it at the level of expert consensus.
The statement sets priorities of expanding disaggregated data collection, increasing representation in research, and ensuring equitable implementation of precision medicine approaches including genomics, multi-omics, and artificial intelligence, while addressing environmental exposures, psychosocial stressors, and policy-related drivers, in service of the American Heart Association's 2028 Impact Goals. Relative to merely describing epidemiological disparities, the statement integrates data, research representation, precision medicine, and structural determinants into an action framework aimed at prevention and improved healthcare delivery. These are strategic recommendations put forward by a scientific statement, expressed in the text as "key priorities include"; no intervention trials or effect evaluations are provided.
Perspective
The statement addresses the epidemiology, prevention, and healthcare delivery of cardiovascular disease and stroke among Hispanic/Latino adults in the United States, and is meant for clinical, public health, and policy settings that need risk understanding refined by heritage group, sex, and disease type; its priorities—disaggregated data, research representation, equitable precision medicine implementation, environmental and psychosocial factors, and policy-related drivers—offer direction for future study design, data infrastructure, and intervention policy.
Readers should still watch: how large the differences are across heritage groups, sexes, and disease types, since the text gives no quantitative values; the time trend and magnitude behind the described widening disparities in hypertension control, obesity, diabetes, and metabolic diseases, which require primary data; the concrete pathways and feasibility of equitable precision medicine implementation (genomics, multi-omics, artificial intelligence) in this population, which remain directional recommendations; and the intervention effects on barriers such as language and insurance access, for which the text provides no evaluation evidence. In addition, the available content is summary-level and lacks figures and data tables, so specific statistics should be verified against the original source.